INSULIN History
Insulin therapy was originally based on repeated injections of short-acting insulins; later long-acting insulins were developed, reducing the number of injections, but not always providing sufficient control of glycemia. This resulted in inadequate prevention of vascular and other complications after several years of treatment.
Today's knowledge suggests that a stricter maintenance of glycemia can prevent or at least reduce diabetic organ damage (1, 2) . Therefore, repeated injections or pump infusion of short-acting insulin have been developed as alternative treatment modalities.
Present status
Mechanical -Multiple insulin schedules involve the injection of four doses of short-acting insulin per day, with one injection of long-acting insulin (3) by the so-called insulin pen. Glycemic control is dramat-ically improved, but compliance remains a problem in view of the multiple injections. Subcutaneous insulin infusion by pumps is another alternative but the size of these devices makes them cumbersome. Local complications, especially infections, can occur (4) .
Common to all these methods is the unphysiological route of administration, resulting in hyperinsulinemia, weight gain, insulin resistance and atheromatosis. Transportal and/or transhepatic routes are physiological.
Bioartificial -One alternative to the technical complexity of insulin pumping systems is the bioartificial pancreas, where living pancreatic cells are encapsulated in an artificial shell, and implanted subcutaneously (5) . If applied under ideal conditions, such a system should result in perfect homeostasis of glycemia, with no immunological reactions as a result of the pancreatic cells being covered by an inert polymer sheath.
Clinical experience with this technique is still limited. The main problems are the viability of the cells, and the difficulty of assembling a cell mass large enough to treat humans consistently for prolonged periods.
Prospects
To obtain reliable mechanical insulin administration, a closed-loop continuous system is the most appropriate solution. Although the pumping technology is available, the most acute need today is for a reliable and lasting glucose sensor (6) . Together with an accurate administration algorithm, such a system would permit optimal control of glycemia.
The pumping systems available are bioincompatible, as they provoke local reactions, infections, and malfunction due to obstruction of the catheters by fibrin and other debris. Improvements are imperative in this field.
Considering that the subcutaneous administration pathway is unphysiological, the intraportal or intraperitoneal routes are more appealing. An illustration of satisfying intraperitoneal administration is the use of four-times-daily insulin in diabetic CAPD patients (7) . In non-uremic diabetics, the peritoneal and portal routes require implantable pumps and catheters (8) . Infectious and thrombotic complications remain a major concern.
The problems of the bioartificial pancreas are the same as for all bioartificial organs. The concept is the most elementary bioartificial organ, aiming only a control of blood glucose. Despite this, the clinical use of the bioartificial pancreas has remained limited, mainly because of the restricted viability of the pancreatic cells. Their functional reserve is in general smaller than that of natural cells, so the other problem is still how to create a large enough cellular mass to maintain insulin secretion and sugar homeostasis in the human body.
ARTIFICIAL HEART

History
Severe cardiac failure irrefutably leads to death. Life-saving attempts to replace this failing function date back more than 50 years, and in fact consecutive developments have been the heart-lung machine, ventricular assist systems, and the total artificial heart. All these modalities are mainly used temporarily, until either recovery of cardiac function or replacement of the failing heart by transplantation.
Current status
Heart support is used with a systolic blood pressure below 80 mmHg, diuresis below 20 ml/h and/or a cardiac index below 2 L/min.m2, in spite of maximal medical support, mainly in relation to open-heart or transplantation surgery, intense cardiac decompensation, therapy-resistant rejection, and massive myocardial infarction or myocarditis.
Heart support can be delivered by continuous (e.g. extracorporeal membrane oxygenation) or by pulsatile flow (ventricle assist device -VAD) (9) . Both techniques are used for short, temporary support. The supporting systems add to the pumping force of the natural heart, that remains operative.
Membrane oxygenation is preferred in urgent con-614 ditions, for its quick and easy insertion, and in patients with concomitant pulmonary dysfunction. VAD can be uni-or biventricular. Both methods however involve continuous contact of the thoracic cavity with the outside world, essentially for energy delivery. This increases the risk of infection.
With the total artificial heart (TAH) the natural heart is removed and replaced by a complete artificial system (10) . Here too in the present state of the art, connection with an external driving unit remains compulsory. The indications are essentially the same as for the support systems, but the T AH can be maintained for a longer period of time, though the risk of thrombotic and infectious complications rises.
The success rate of all these is 50% at best. The prognosis is bad in acute and critical conditions, in patients older than 40, in chronic ischemia, in association with acute tubular necrosis, and in patients with myocardial infarction and treatment-resistant heart rejection.
The main complications are infection (especially in immune suppressed patients) and thrombosis (11, 12), the latter being mainly attributed to the foreign surface structure and to flow separation, i.e. stagnation of blood in isolated low-flow areas. Thrombosis can be prevented by anticoagulants, though this clearly raises the risk of hemorrhagic complications.
Prospects
In the immediate future, corrections should be introduced into existing artificial heart systems, to improve their biocompatibility and to reduce the complication rate. The search for totally implantable systems, without an external driving source or energy transmission, is a priority, to prevent infectious complications (13) .
In the distant future, it may become possible to develop a bioartificial heart, especially using new acquisitions such as genetic engineering. The bioartificial concept might also be useful for replacing only limited functions of the heart, e.g. endocrinological production of hormones such as atriopeptide.
ARTIFICIAL LUNG
History
Attempts to enhance oxygen delivery to the blood in case of lung failure have been made for more than 100 years, starting with subcutaneous oxygen injections, followed by oxygen delivery through the natural airways and mechanical ventilation, up to blood oxygenation by extracorporeal mechanical oxygenators (14) .
Present status
Extracorporeal mechanical pump oxygenators can be divided into bubble and membrane oxygenators, the first being historical and technical predecessors of the latter. Both systems are based on the concept of a direct blood-gas interface. They may remain in function for several consecutive days.
As with the artificial heart, the configuration and function of the lung can hardly be reconciled with the current concept of bioartificial organs. At best, there will remain a need for a pumping system, related to a membrane. Thus, the only logical use of bioartificial technology might be based on exploitation of the functional endothelium as an oxygen transport system, though this would pose the problem of a proper biocompatible support.
Prospects
The main problem with membrane oxygenation is its short-lasting utility, mainly due to bioincompatibility: clotting, complement and granulocyte activation and suppression of the immune system (15) .
Several corrections of the existing systems might improve biocompatibility: optimisation of blood flow patterns and blood mixing, adaptation of the thickness of the membrane, covering the membrane pores with material permeable to gas and impermeable to fluid, and improvement of biomaterials.
The final aim is to develop an intracorporeal, implantable, pumpless oxygenator. Major problems are the anatomical relation with the thoracic cavity, the need for adaptation to enhanced oxygen requirements during exercise, and the need for a continuously efficient system for prolonged periods, preferably working on air.
Furthermore, mechanical lung support does not provide any of the lungs' routine hormonal and enzymatic functions. Here, encapsulated bioartificial systems might be of additional help.
ARTIFICIAL LIVER
History
Fulminant hepatitis and terminal cirrhosis conduct to fatal liver failure, unless transplantation or spontaneous convalescence ensues. Artificial liver support offers an opportunity to bridge this period of lifethreatening organ failure. During the last 20 years, several -mostly empirical -attempts have been undertaken to replace the failing liver function.
Present status
Mechanical -Most available artificial liver support systems are mechanical, and not specific for hepatic disease, e.g. hemodialysis, hemoperfusion, hemofiltration, hemodiafiltration, plasmapheresis, etc. (16) . These methods mainly aim at blood detoxification, disregarding other liver functions, such as synthesis and metabolism. Detoxification has mainly focussed on hydrophilic compounds, whereas many important hepatic toxins are lipophilic.
Therefore, mechanical liver support today remains mainly empirical, with an unpredictable outcome. These treatment modalities further carry their own complication risks, e.g. thrombocytopenia (hemoperfusion), or immune and clotting deficiency and ARDS (plasmapheresis).
It cannot be denied that the most thrilling results with artificial liver have been obtained during treatment of paracetamol intoxication; it is not clear whether this success is related to a correction of hepatic failure or simply to an elimination of the drug.
Bioartificial -In view of the complex physiology of the liver, attempts have been made to use living liver tissue or hepatic enzymes to support liver function. A current example is heterologous liver perfusion. These methods too, however, are generally based on empirical concepts.
Recent attempts to implant encapsulated liver cells in diseased animals might at least in theory offer an opportunity to restore hepatic metabolic function (17) . This method might be especially helpful in transforming lipophilic to hydrophilic substances, after which they can be eliminated by the kidneys or dialysis. These hybrid systems lack a drain for bile. Questions arise about long-term cell viability in a potentially toxic environment, and the extent of the cell mass that will be needed for adequate detoxification.
Prospects
In the absence of any reliable replacement system other than transplantation, and in view of the natural liver's complex function the future for the treatment of hepatic failure might be bioartificial more than for any other artificial organ.
It is acknowledged that the present hybrid livers are complicated but still incomplete; they must be improved before they can be considered reliable in clinical conditions.
The need for an adequate system remains urgent, in view of the high mortality of liver failure.
PLASMAPHERESIS
History
Plasmapheresis eliminates large noxious substances from the blood, and has been used for the treatment of various -especially immune -diseases for the last 20-30 years (18) . Until recently, it essentially offered non-selective elimination, followed by equivoluminous replacement by plasma substitution fluids.
Present status
Mechanical -Plasmapheresis can be either centrifugal, or based on ultrafiltration through large pores. The first method achieves separation and selective elimination of plasma, and also of plasma compounds. The second method resembles hemodialysis, alhough the rationale is different.
The results of plasmapheresis have somehow been disappointing, related to the gradual perception that this technique is valuable only in conjuction with other therapeutic regimens. A further drawback it its lack of selectivity, whereby not only pathogenic but also vital proteins, e.g. of the coagulation or immune system, are eliminated.
At the moment, there are several accepted indications: hyperviscosity, Goodpasture, thrombotic thrombocytopenic purpura, myasthenia gravis, Waldenstr6m, hyperglobulinemia, vasculitis, cholestatic pruritus, chronic relapsing polyneuritis, scleroderma and polymyositis. Additional indications, especially in severe disease, are: Guillain-Barre, rapidly progressive glome-rulonephritis, hemolytic uremic syndrome and lupus erythematodes disseminatus.
Prospects
The main problem with plasmapheresis today isas we have said -its limited selectivity. More selective elimination might be achieved through cascade filtration, cryofiltration, thermofiltration, or immunoselective (protein A) and non-immunoselective plasma absorption (lipids).
Another promising application is the selective separation of immune cells, that are reinfused after stimulation, e.g. to enhance the phagocytic destruction of carcinoma.
However, with the advent of newer, stronger and more specific pharmacological means, plasmapheresis at least in part will very likely become superfluous.
ARTIFICIAL KIDNEY
History
Although the concept has existed for many years, the practical achievement of hemodialysis only dates from World War II, with the advent of reliable anticoagulation. Although many corrections have been introduced since then, the basic principle remains the same, with some newer variants such as hemodiafiltration, hemofiltration and paired filtration dialysis. Over time, dialysis alone or in combination with transplantation has enabled renal patients to survive beyond the terminal stage for two decades or more. The therapeutic spectrum was further expanded by the advent of peritoneal dialysis, which was the first opportunity to offer continuous treatment, and by continuous arterio-venous hemofiltration, a continuous therapy mainly used in intensive care.
Present status
Mechanical -Several technical modalities make hemodialysis or related techniques possible. Efficiency was better controlled after the introduction of kinetic modelling.
The specific bioincompatibility of the current dialysis modalities has been recognized as a frequent source of acute and chronic complications (19) .
Corrections aimed at reducing these problems have been introduced regularly.
Although the current vascular access involves two needles in an arterio-venous fistula, singleneedle dialysis offers a valuable alternative, by delivering adequate dialysis, with only half the fistula damage (20) .
Current hemodialysis accomplishes blood contact with toxin-free dialysate through a semipermeable membrane. If dialysate is not endotoxin-free, transmembrane transfer of pyrogens can occur, especially when hemodialysis uses large-pore dialyzers (21) . This might be prevented by the use of sterile and endotoxin-free dialysate, or by strategies that prevent transmembrane dialysate backfiltration, e.g. hemofiltration, or hemodiafiltration.
Bioartificiaf -In the last few years, attempts have been made to develop a bioartificial kidney, using cultured tubular cells for the regeneration of ultrafiltrate or dialysate (22) . Although attractive at first glance, this concept has several drawbacks, related to the specificity and polarity of renal cells, the cell mass necessary for minimal renal function, the viability of these cells in a toxic uremic environment, and the difficulty of reproducing the complex anatomical arrangement of the tubular system, especially Henle's loop.
Prospects
There is an obvious tendency to shorter dialysis times, which calls for careful monitoring of dialysis efficiency with kinetic methods. The reliability and feasibility of urea kinetics should be improved, conceivably by increasing the number of concentration assessments, e.g. by repeated or continuous sensing of blood or dialysate urea. Short intermittent treatment sessions impose additional stress that might be reduced by slower and more gradual dialysis, the ideal in this context being a continuous or semi-continuous treatment as is offered in CAPO.
Attempts to develop a wearable dialysis system have been made for many years but all have failed on bulkiness and inefficiency. The development of bioartificial technology might add an extra dimension, but remains hampered by a number of methodological problems.
With a better knowledge of the uremic syndrome, one might aim for selective elimination of specific uremic toxins, by absorption from the blood or the gastro-intestinal tract. Experience with selective potassium and phosphorus absorbants teaches however, that most of these agents do not eliminate the need for dialysis. Some of them, e.g. aluminium, may cause specific toxic problems themselves.
ARTIFICIAL BLOOD
History
Blood substitution by donor blood became only possible after the recognition of blood groups. Limitations are the lack of donors and growing demand. The concept of artificial blood became more attractive with the recognition of the risk of blood incompatibility, immunological reactions and transmission of major infections, e.g. AIOS or hepatitis.
Current status
Injectable oxygen carriers are still under development. There are two major types: a) the fluorocarbons (23); b) hemoglobin, either encapsulated or polymerized (24) .
Major problems are the realisation of optimum oxygen transport, solubility, and elimination. Accumulation in the reticulo-endothelial system is a possible problem.
When using artificial blood, other characteristics should be considered: fluorocarbons behave like contrast agents with any major imaging technique (X-ray, MRI, CAT-scan, echography); hemoglobinbased artificial blood results in a physiological oxygen carrier status but the main problem is fast elimination by the kidneys, if unmodified hemoglobin is used. Polymerisation or encapsulation by mono-or multilamellar phospholipids is one way of tackling this problem.
A major advantage of hemoglobin is its ready availability, from outdated human blood, other animal species, or biotechnology. To obtain optimum efficacy, the concomitant presence of electrolytes and buffer, as in the red blood cell, is important. So encapsulation should, if possible, mimick the intraglobular condition.
As an alternative to encapsulation, hemoglobins can be polymerized, mainly by pyridoxylation. These hemoglobins are not eliminated by the kidney, and are thus not nephrotoxic. Clinical trials however have only employed minimal doses. As large molecules they can influence colloid osmotic pressure, and their oxygen affinity might change during their stay in the body.
